Drug pipeline brings $80m more to Synta
523183
Synta Pharmaceuticals Corp. plans to announce today that it has raised $80 million from a group of private investors, bringing to more than $200 million the amount the Lexington drug developer has raised since 2002.
296490
The small pharmaceutical firm signs another big deal.
731679
Cytyc Corp. of Marlborough said it will pay $160 million for Proxima Therapeutics Inc. of Alpharetta, Ga., the maker of MammoSite, a device that treats breast-cancer tumors with radiation targeting the lumpectomy site. Cytyc will pay an additional fee based on sales growth over two years. Cytyc said the acquisition boosts the company's role as a major supplier of products ...
642132
The pharmaceutical's net revenue jumps 77%.
748684
Shares of Biomira Inc., a Canadian drug developer, jumped 94 percent and Merck KGaA, Germany&#39;s fourth-largest drugmaker, rose as much as 6.4 percent after the companies said data from
471781
The company is ready to handle competition from generics.
517827
The drugmaker signed a deal to authorize a generic form of its osteoporosis drug Fosamax, which has annual sales of $3 billion, making it the worldâs top-selling drug for osteoporosis.
218452
The drug maker said net income rose 6 percent to $926.3 million and it raised its outlook for the year.
75091
The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
335426
The newly formed pharmaceutical group Sanofi-Aventis published third-quarter sales figures showing a 10.7 percent increase over 12 months in line with expectations.
555013
The pharmaceutical firm releases fourth-quarter financials.
727152
New developments are brewing at the pharmaceutical.
639985
As part of its push to become a bigger player in cancer drugs, Genzyme Corp. of Cambridge said yesterday it will buy out business partner Bioenvision Inc. of New York for $345 million , consolidating its ownership of a cancer treatment to which the two companies had been sharing rights.
327409
The pharma raises cash ahead of an FDA hearing.
219400
The former will take over development of the latter's drug.
147168
The approval of a new drug is a long-term opportunity.
731230
The biotech mines extra value from its compound library.